文献速递垂体与肾上腺疾病

新生儿筛查对先天性肾上腺皮质增生症患者成年身高的影响

Impact of Newborn Screening on Adult Height in Patients With Congenital Adrenal Hyperplasia (CAH).
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

该研究基于德国先天性肾上腺皮质增生症(CAH)登记库,回顾性分析600例经典型CAH患者的近成年身高数据,其中101例(16.8%)接受了新生儿筛查。结果显示,新生儿筛查与男性CAH患者及单纯男性化型CAH患者近成年身高改善相关,但在女性患者及失盐型CAH患者中未观察到筛查对近成年身高的影响。

要点

  • 新生儿筛查与男性CAH患者近成年身高显著改善相关(P = .033)。
  • 单纯男性化型CAH患者接受筛查者近成年身高显著优于未筛查者(P = .034)。
  • 女性患者及失盐型CAH患者中,新生儿筛查对近成年身高无显著影响。

核心结论

  • 数据提示新生儿筛查可能与男性CAH患者及单纯男性化型CAH患者近成年身高改善相关。

研究设计与样本

  • 回顾性分析德国CAH登记库中600例经典型CAH患者(227例男性)的近成年身高、靶身高及新生儿筛查信息。
  • 101例(16.8%)患者接受了新生儿筛查,所有患者接受氢化可的松治疗,伴或不伴氟氢可的松。
  • 采用按性别和表型校正/分层的线性回归模型评估新生儿筛查效应(SAS 9.4)。

主要发现

  • 靶身高校正后的近成年身高在筛查组为-0.25 SDS(95%CI -0.44至-0.06),未筛查组为-0.44 SDS(95%CI -0.52至-0.36),P = .069。
  • 女性患者中筛查对近成年身高无影响。
  • 男性患者中,筛查组近成年身高显著优于未筛查组(P = .033)。
  • 按CAH表型分层后,筛查对失盐型CAH患者近成年身高无影响。
  • 单纯男性化型CAH患者中,筛查组靶身高校正近成年身高为0.15 SDS(95%CI -0.28至0.59),未筛查组为-0.35 SDS(95%CI -0.52至-0.18),P = .034。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Treatment of children with classical congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is challenging. Linear growth and adult height are compromised according to recent publications. However, most of these data were obtained in the era before CAH newborn screening. DESIGN: Body height of patients with classical CAH diagnosed before and after the establishment of newborn screening were analyzed retrospectively. PATIENTS AND METHODS: We identified 600 patients with classical CAH (227 male) with data on near-adult height (NAH), target height (TH), and information on newborn screening from the electronic German CAH registry (German Society for Paediatric Endocrinology and Diabetology). Newborn screening was performed in 101 (16.8%) patients. All patients received hydrocortisone with or without fludrocortisone.To assess the effects of newborn screening, a linear regression model adjusted/stratified for sex and phenotype was used (SAS 9.4). RESULTS: TH corrected NAH (mean; 95% confidence interval) was closer to 0 in patients with CAH and newborn screening [-0.25 standard deviation score (SDS); -0.44 to -0.06] than in patients without newborn screening (-0.44 SDS; -0.52 to -0.36) (P = .069). Screening had no effect on NAH in female patients. In male patients, NAH was significantly better (P = .033) with screening than without screening. After stratifying for CAH phenotype, screening did not affect the NAH of patients with salt-wasting CAH. Patients with simple-virilizing CAH had a significantly better cNAH (P = .034) with screening (0.15 SDS; -0.28-0.59) than without screening (-0.35 SDS; -0.52 to -0.18). CONCLUSIONS: Our data suggest that newborn screening might be associated with improved NAH in male CAH patients and in patients with simple-virilizing CAH.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Hoyer-Kuhn H, Eckert AJ, Binder G, et al. Impact of Newborn Screening on Adult Height in Patients With Congenital Adrenal Hyperplasia (CAH). J Clin Endocrinol Metab. 2023. PMID: 37256841. doi:10.1210/clinem/dgad307

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。